NASDAQ:BLUE - bluebird bio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$180.60 +0.30 (+0.17 %)
(As of 07/15/2018 04:00 PM ET)
Previous Close$180.60
Today's Range$178.60 - $183.00
52-Week Range$85.65 - $236.17
Volume491,559 shs
Average Volume1.23 million shs
Market Capitalization$9.05 billion
P/E Ratio-23.42
Dividend YieldN/A
bluebird bio logobluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio10.80
Quick Ratio10.80


Trailing P/E Ratio-23.42
Forward P/E Ratio-19.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.43 million
Price / Sales255.48
Cash FlowN/A
Price / CashN/A
Book Value$33.11 per share
Price / Book5.45


EPS (Most Recent Fiscal Year)($7.71)
Net Income$-335,640,000.00
Net Margins-857.55%
Return on Equity-27.61%
Return on Assets-23.05%


Outstanding Shares50,120,000
Market Cap$9,051.49

The Truth About Cryptocurrencies

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) issued its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($2.31) earnings per share for the quarter, missing the consensus estimate of ($2.01) by $0.30. The biotechnology company had revenue of $15.96 million for the quarter, compared to analysts' expectations of $5.85 million. bluebird bio had a negative return on equity of 27.61% and a negative net margin of 857.55%. The firm's quarterly revenue was up 133.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.68) EPS. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

24 analysts have issued twelve-month price targets for bluebird bio's shares. Their predictions range from $122.00 to $250.00. On average, they expect bluebird bio's share price to reach $214.75 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price. View Analyst Ratings for bluebird bio.

What is the consensus analysts' recommendation for bluebird bio?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 8 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:
  • 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
  • 2. Maxim Group analysts commented, "bluebird reported YE-2017 with $22M in revenue (collaborative/licensing revenue) and a net loss of $336M. Operating expenses have increased as clinical programs advance to later stages of development. The company ended the period with $1.6B in cash, sufficient runway into 2021 at the current burn rate." (2/22/2018)
  • 3. Cantor Fitzgerald analysts commented, "Lining Up for Three Marketing Applications. bluebird plans to file for European approval of LentiGlobin in transfusion-dependent b-thalassemia (non-b0/b0) in 2H18, followed by bb2121 in relapsed/refractory multiple myeloma and Lenti-D in cerebral adrenoleukodystrophy in 2019. As a reminder, bb2121 is being investigated in a Phase 3 study, KarMMa, which is being conducted by bluebird’s bb2121 development partner, Celgene (CELG – Neutral, covered by Mara Goldstein)." (2/21/2018)
  • 4. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 45)
  • Mr. Jeffrey T. Walsh, Chief Financial and Strategy Officer (Age 52)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 47)
  • Mr. Jason F. Cole, Chief Legal Officer & Sec. (Age 45)
  • Dr. David M. Davidson, Chief Medical Officer (Age 54)

Has bluebird bio been receiving favorable news coverage?

Media headlines about BLUE stock have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. bluebird bio earned a coverage optimism score of 0.15 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.14 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Xact Kapitalforvaltning AB (0.01%), State of Alaska Department of Revenue (0.01%) and XR Securities LLC (0.00%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Which institutional investors are buying bluebird bio stock?

BLUE stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, XR Securities LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for bluebird bio.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $180.60.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $9.05 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-335,640,000.00 in net income (profit) each year or ($7.71) on an earnings per share basis. bluebird bio employs 479 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  694 (Vote Outperform)
Underperform Votes:  309 (Vote Underperform)
Total Votes:  1,003
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.